Next Article in Journal
Functional Phenotypes of Intraplaque Macrophages and Their Distinct Roles in Atherosclerosis Development and Atheroinflammation
Next Article in Special Issue
PTML Modeling for Pancreatic Cancer Research: In Silico Design of Simultaneous Multi-Protein and Multi-Cell Inhibitors
Previous Article in Journal
Prevalence of Pruritus and Association with Anxiety and Depression in Patients with Nonalcoholic Fatty Liver Disease
Previous Article in Special Issue
Macrophage C/EBPδ Drives Gemcitabine, but Not 5-FU or Paclitaxel, Resistance of Pancreatic Cancer Cells in a Deoxycytidine-Dependent Manner
 
 
Article

An In Vitro Investigation into Cryoablation and Adjunctive Cryoablation/Chemotherapy Combination Therapy for the Treatment of Pancreatic Cancer Using the PANC-1 Cell Line

1
CPSI Biotech, Owego, NY 13827, USA
2
GI Cryo, Inc., Owego, NY 13827, USA
3
Center for Translational Stem Cell and Tissue Engineering, Binghamton University, Binghamton, NY 13902, USA
4
Department of Biological Sciences, Binghamton University, Binghamton, NY 13902, USA
5
Department of Medicine-Gastroenterology, Baylor College of Medicine, Houston, TX 77030, USA
6
Department of Medicine, University of Texas Health Science Center, Houston, TX 77030, USA
7
Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA
8
Elkins Pancreas Center, Dan L Duncan Comprehensive Cancer Center, Houston, TX 77030, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Satoshi Wada
Biomedicines 2022, 10(2), 450; https://doi.org/10.3390/biomedicines10020450
Received: 7 January 2022 / Revised: 8 February 2022 / Accepted: 9 February 2022 / Published: 15 February 2022
(This article belongs to the Special Issue Pancreatic Cancer: From Mechanisms to Therapeutic Approaches)
As the incidence of pancreatic ductal adenocarcinoma (PDAC) continues to grow, so does the need for new strategies for treatment. One such area being evaluated is cryoablation. While promising, studies remain limited and questions surrounding basic dosing (minimal lethal temperature) coupled with technological issues associated with accessing PDAC tumors and tumor proximity to vasculature and bile ducts, among others, have limited the use of cryoablation. Additionally, as chemotherapy remains the first-line of attack for PDAC, there is limited information on the impact of combining freezing with chemotherapy. As such, this study investigated the in vitro response of a PDAC cell line to freezing, chemotherapy, and the combination of chemotherapy pre-treatment and freezing. PANC-1 cells and PANC-1 tumor models were exposed to cryoablation (freezing insult) and compared to non-frozen controls. Additionally, PANC-1 cells were exposed to varying sub-clinical doses of gemcitabine or oxaliplatin alone and in combination with freezing. The results show that freezing to −10 °C did not affect viability, whereas −15 °C and −20 °C resulted in a reduction in 1 day post-freeze viability to 85% and 20%, respectively, though both recovered to controls by day 7. A complete cell loss was found following a single freeze below −25 °C. The combination of 100 nM gemcitabine (1.1 mg/m2) pre-treatment and a single freeze at −15 °C resulted in near-complete cell death (<5% survival) over the 7-day assessment interval. The combination of 8.8 µM oxaliplatin (130 mg/m2) pre-treatment and a single −15 °C freeze resulted in a similar trend of increased PANC-1 cell death. In summary, these in vitro results suggest that freezing alone to temperatures in the range of −25 °C results in a high degree of PDAC destruction. Further, the data support a potential combinatorial chemo/cryo-therapeutic strategy for the treatment of PDAC. These results suggest that a reduction in chemotherapeutic dose may be possible when offered in combination with freezing for the treatment of PDAC. View Full-Text
Keywords: ablation; cryosurgery; freeze dose; pancreatic cancer; gemcitabine; oxaliplatin ablation; cryosurgery; freeze dose; pancreatic cancer; gemcitabine; oxaliplatin
Show Figures

Figure 1

MDPI and ACS Style

Baust, J.M.; Santucci, K.L.; Van Buskirk, R.G.; Raijman, I.; Fisher, W.E.; Baust, J.G.; Snyder, K.K. An In Vitro Investigation into Cryoablation and Adjunctive Cryoablation/Chemotherapy Combination Therapy for the Treatment of Pancreatic Cancer Using the PANC-1 Cell Line. Biomedicines 2022, 10, 450. https://doi.org/10.3390/biomedicines10020450

AMA Style

Baust JM, Santucci KL, Van Buskirk RG, Raijman I, Fisher WE, Baust JG, Snyder KK. An In Vitro Investigation into Cryoablation and Adjunctive Cryoablation/Chemotherapy Combination Therapy for the Treatment of Pancreatic Cancer Using the PANC-1 Cell Line. Biomedicines. 2022; 10(2):450. https://doi.org/10.3390/biomedicines10020450

Chicago/Turabian Style

Baust, John M., Kimberly L. Santucci, Robert G. Van Buskirk, Isaac Raijman, William E. Fisher, John G. Baust, and Kristi K. Snyder. 2022. "An In Vitro Investigation into Cryoablation and Adjunctive Cryoablation/Chemotherapy Combination Therapy for the Treatment of Pancreatic Cancer Using the PANC-1 Cell Line" Biomedicines 10, no. 2: 450. https://doi.org/10.3390/biomedicines10020450

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop